Article info

Download PDFPDF
Comment on ‘Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy’

Authors

  1. Correspondence to Dr Thomas Botton, Team 1, INSERM U1065, Nice 06204, France; thomas.botton{at}unice.fr
View Full Text

Citation

Botton T, Passeron T, Rocchi S
Comment on ‘Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy’

Publication history

  • Received December 6, 2019
  • Accepted December 9, 2019
  • First published December 18, 2019.
Online issue publication 
July 20, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.